>

FDA Approves First Needle-Free Treatment for Severe Allergic Reactions

Nasal Spray Provides Alternative to Epinephrine Auto-Injectors

Neffy Nasal Spray is Seen as a Breakthrough in Allergy Treatment

The Food and Drug Administration (FDA) has approved the first nasal spray for the emergency treatment of allergic reactions in adults and certain children. Neffy is the first needle-free option for severe allergic reactions that the FDA has approved. For years, people at risk of severe allergic reactions have had to rely on epinephrine auto-injectors like EpiPen and Auvi-Q.

Neffy is administered by spraying it into one nostril. The drug works by blocking the release of histamines, which are chemicals that trigger allergic reactions. Neffy is expected to be available in pharmacies within the next few months.

The FDA's approval of Neffy is a significant milestone in the treatment of severe allergic reactions. The nasal spray provides a needle-free alternative to epinephrine auto-injectors, which can be difficult to use for some people. Neffy is also less likely to cause side effects than epinephrine auto-injectors, such as anxiety and heart palpitations.